Last reviewed · How we verify
NCT07193017
The Effect of BIPAP on Diaphragmatic Function
trial testing BIPAP in BIPAP Biphasic Intermittent Positive Airway Pressure in 30 participants. Not yet recruiting.
15 October 2026
Quick facts
| Lead sponsor | Istanbul Demiroglu Bilim University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 15 October 2025 |
| Primary completion | 15 October 2026 |
| Estimated completion | 15 June 2027 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- BIPAP
Conditions studied
- BIPAP Biphasic Intermittent Positive Airway Pressure — all drugs for BIPAP Biphasic Intermittent Positive Airway Pressure →
- Diaphragm Issues — all drugs for Diaphragm Issues →
- Ultrasound Diagnostics — all drugs for Ultrasound Diagnostics →
- COPD (Chronic Obstructive Pulmonary Disease) — all drugs for COPD (Chronic Obstructive Pulmonary Disease) →
Sponsor
Istanbul Demiroglu Bilim University
Who can join
Adults 40 to 80, any sex, with BIPAP Biphasic Intermittent Positive Airway Pressure or Diaphragm Issues. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research is designed to evaluate how long-term treatment with Bilevel Positive Airway Pressure (BiPAP) influences diaphragm function in patients with Chronic Obstructive Pulmonary Disease (COPD) who suffer from chronic hypercapnic respiratory failure. The diaphragm is the primary muscle of breathing, and its dysfunction is linked to unfavorable clinical outcomes such as higher mortality rates and frequent hospitalizations. In this prospective cohort study, COPD patients starting BiPAP therapy based on clinical indication will be monitored through repeated ultrasound assessments of diaphragm structure and function together with pulmonary function testing, respiratory muscle strength evaluation, dyspnea. The main outcome of interest is the change in diaphragm thickness in inspiration, thickness in expiration, diaphragm thickening fraction (DTF), diaphragm maximum contraction velocity and maximum relaxation velocity across a 6 weeks as a early time and 12 months for long time follow-up period. Secondary measures include hospital admissions, and one-year survival. The study is expected to generate valuable evidence about the link between non-invasive ventilation and diaphragm function, which may contribute to optimizing treatment strategies for COPD patients with advanced respiratory failure.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07193017
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BIPAP
Trials testing the same drug.
- NCT06988111 — Management of Post-operative Respiratory Failure by Using NIV and High Velocity Nasal Insufflation (HVNI) · NA · not yet recruiting
- NCT06567587 — Dexmedtomodine Effect on Agitated Psychotic Patients Suffer COPD · completed
- NCT04205422 — Effect of Two Modes of Mechanical Ventilation on Metabolic Demands and Respiratory Mechanics · NA · unknown
Other Istanbul Demiroglu Bilim University trials
Trials by the same sponsor.
- NCT07317531 — Effects of Expiratory Muscle Training Added to Pulmonary Rehabilitation in Patients With Bronchiectasis · NA · not yet recruiting
- NCT06403397 — Assessing the Impact of Monitor Maintenance Package Utilization · NA · not yet recruiting
- NCT06403410 — Delirium Prevention Guideline for Intensive Care Patients · NA · not yet recruiting
- NCT06418009 — Determination of the Effect of Cold Needle on Invasive Pain Cannulation · NA · active not recruiting
- NCT05533398 — Stress Ball Use on Anxiety · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07193017 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul Demiroglu Bilim University
- Last refreshed: 25 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07193017.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing